A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of JADE101 in Participants with IgAN June 5, 2026
Interim Results of a Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JADE101 in Healthy Volunteers June 5, 2026
Translational Framework to Predict Clinical Responses to APRIL Blockade for Development of JADE101 November 8, 2025